{"id":373899,"date":"2026-10-15T21:22:52","date_gmt":"2026-10-15T15:52:52","guid":{"rendered":"https:\/\/forumias.com\/blog\/?p=373899"},"modified":"2026-10-15T21:22:52","modified_gmt":"2026-10-15T15:52:52","slug":"margin-caps-on-cancer-drugs-could-there-be-more-on-the-anvil","status":"publish","type":"post","link":"https:\/\/forumias.com\/blog\/margin-caps-on-cancer-drugs-could-there-be-more-on-the-anvil\/","title":{"rendered":"Margin caps on cancer drugs, could there be more on the anvil?"},"content":{"rendered":"

Source: <\/strong>The post \u201cMargin caps on cancer drugs, could there be more on the anvil?\u201d <\/strong>has been created based on “Margin caps on cancer drugs, could there be more on the anvil?\u201d <\/strong>published in \u201cThe Hindu<\/strong>\u201d on 15th October 2026.<\/p>\n

UPSC Syllabus: GS-2-Governance<\/strong><\/p>\n

Context: <\/strong>The Central Government has approved a cap on trade margins of non-scheduled anti-cancer drugs to address high medicine prices and make cancer treatment more affordable. The move comes amid concerns raised by the Supreme Court regarding excessive mark-ups and the need to protect patients from high out-of-pocket healthcare expenditure.<\/p>\n

Key features of the government\u2019s move<\/strong><\/h2>\n
    \n
  1. The Centre has approved a cap on trade margins of non-scheduled anti-cancer drugs at 30% of the Maximum Retail Price (MRP).<\/li>\n
  2. The measure is expected to reduce medicine prices by up to 70% and help cancer patients save approximately \u20b92,500 crore annually.<\/li>\n
  3. A committee of experts under the Directorate General of Health Services (DGHS) is finalising the list of medicines to be covered, while the National Pharmaceutical Pricing Authority (NPPA) will take the final decision.<\/li>\n
  4. The National List of Essential Medicines (2022) includes 388 drugs, covering 63 anti-cancer drugs.<\/li>\n<\/ol>\n

    Rationale behind the measure<\/strong><\/h2>\n
      \n
    1. Excessive trade mark-ups: <\/strong>NPPA data analysis indicates that non-scheduled anti-cancer drugs carry an average trade mark-up of approximately 170%, reaching up to 700% in certain cases.<\/li>\n
    2. Price variations: <\/strong>Medicine prices and discounts vary substantially across retail pharmacies, hospitals and e-pharmacies.<\/li>\n
    3. High financial burden: <\/strong>Cancer treatment imposes a significant out-of-pocket expenditure burden on patients and their families.<\/li>\n
    4. Supreme Court intervention: <\/strong>The issue gained attention following a breast cancer drug Ribociclib case in Kerala and petitions seeking regulatory action against high prices of medicines and medical devices.<\/li>\n
    5. Previous success: <\/strong>In February 2019, the NPPA capped trade margins on 42 selected non-scheduled anti-cancer drugs, reducing MRPs by up to 91% and reportedly generating annual savings of \u20b9984 crore across 526 brands.<\/li>\n<\/ol>\n

      Possibility of extending price controls<\/strong><\/h2>\n
        \n
      1. The Supreme Court has reportedly questioned why similar trade margin caps cannot be extended to other non-scheduled medicines and medical consumables in the interest of patients.<\/li>\n
      2. State regulators in Maharashtra, Rajasthan and Karnataka have also raised concerns about steep mark-ups on medicines and consumables used in hospitals.<\/li>\n
      3. The anti-cancer drug market comprises approximately 225 drugs and 500 formulations, with an estimated annual turnover of \u20b912,500 crore. Scheduled cancer drugs account for around \u20b92,250 crore, while the remaining market comprises non-scheduled drugs.<\/li>\n<\/ol>\n

        Concerns and challenges<\/strong><\/h2>\n
          \n
        1. Pharmaceutical industry: <\/strong>The Indian Pharmaceutical Alliance has argued that medicine prices in India are among the lowest globally and has called for adequate trade margins.<\/li>\n
        2. Hospitals: <\/strong>The Association of Healthcare Providers of India has emphasised the need for evidence-based pricing, pointing to high operating costs and capital investments. It has stated that many hospitals have operating margins of 8\u201312%.<\/li>\n
        3. Balanced regulation: <\/strong>Pricing decisions must distinguish between excessive mark-ups and legitimate costs involved in manufacturing, distribution and healthcare delivery.<\/li>\n<\/ol>\n

          Way Forward<\/strong><\/h2>\n
            \n
          1. Evidence-based regulation: <\/strong>The government should extend margin caps to other medicines and medical consumables after examining market data, cost structures and patient affordability.<\/li>\n
          2. Transparent pricing: <\/strong>Hospitals, pharmacies and e-pharmacies should disclose medicine prices and applicable discounts to reduce information asymmetry and unjustified price variations.<\/li>\n
          3. Strengthen monitoring: <\/strong>The NPPA and State drug regulators should regularly monitor trade margins and take action against excessive mark-ups.<\/li>\n
          4. Stakeholder consultation:<\/strong> The government should consult pharmaceutical companies, hospitals, distributors and patient groups to balance affordability with the financial sustainability of healthcare services.<\/li>\n
          5. Improve access to affordable medicines:<\/strong> The government should strengthen the availability of quality generic medicines and affordable treatment options for vulnerable patients.<\/li>\n
          6. Periodic review: <\/strong>The impact of price controls on medicine prices, availability and supply should be assessed regularly to prevent shortages and ensure continued access to essential treatments.<\/li>\n<\/ol>\n

            Conclusion: <\/strong>The government\u2019s decision is an important step towards affordable and equitable healthcare. Extending similar controls to other medicines and medical consumables may be considered through evidence-based regulation, transparent pricing and stakeholder consultation, while ensuring the sustainability of pharmaceutical supply chains and healthcare institutions.<\/p>\n

            Question: <\/strong>The government\u2019s move to cap trade margins on non-scheduled anti-cancer drugs is aimed at making healthcare more affordable. Discuss the rationale behind this measure and examine the possibility of extending similar price controls to other medicines and medical consumables.<\/p>\n

            Source: <\/strong>The Hindu<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

            Source: The post \u201cMargin caps on cancer drugs, could there be more on the anvil?\u201d has been created based on “Margin caps on cancer drugs, could there be more on the anvil?\u201d published in \u201cThe Hindu\u201d on 15th October 2026. UPSC Syllabus: GS-2-Governance Context: The Central Government has approved a cap on trade margins of… Continue reading Margin caps on cancer drugs, could there be more on the anvil?<\/span><\/a><\/p>\n","protected":false},"author":10320,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"categories":[1230],"tags":[300,212,10498],"class_list":["post-373899","post","type-post","status-publish","format-standard","hentry","category-9-pm-daily-articles","tag-governance","tag-gs-paper-2","tag-the-hindu","entry"],"jetpack_featured_media_url":"","views":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/373899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/users\/10320"}],"replies":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/comments?post=373899"}],"version-history":[{"count":0,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/373899\/revisions"}],"wp:attachment":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/media?parent=373899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/categories?post=373899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/tags?post=373899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}